pyrazines has been researched along with Autoimmune Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y; Ran, F; Wang, ML; Yang, D; Zhang, D; Zhang, Z; Zhao, G | 1 |
| Cvek, B; Škrott, Z | 1 |
| Mel'nikova, EV; Robinson, MV; Trufakin, VA | 1 |
| Blancho, G; Branchereau, J; Breimer, ME; Charreau, B; Châtelais, M; Cowan, PJ; Cozzi, E; Crossan, C; d'Apice, AJ; Daha, MR; Dilek, N; Diswall, M; Duchi, R; Galli, C; Hervouet, J; Klar, N; Lagutina, I; Lazzari, G; Le Bas-Bernardet, S; Minault, D; Nottle, MB; Perota, A; Poirier, N; Renaudin, K; Robson, SC; Sachs, DH; Salvaris, EJ; Scobie, L; Simioni, P; Soulillou, JP; Takeuchi, Y; Tillou, X; Vanhove, B; Yamada, K | 1 |
| Dasanu, CA | 1 |
| Khosroshahi, A; Stone, JH | 1 |
| Fingerle-Rowson, G; Goldschmidt, H; Ho, AD; Neben, K; Pham, M; Schmitt, S; Storch-Hagenlocher, B | 1 |
| Groll, M; Huber, EM | 1 |
| Fierabracci, A | 1 |
| Gault, RA; Mattingly, LH; Murphy, WJ | 1 |
| Baumann, H; Jacob, CO; Kambayashi, T; Lazarus, DD; Strassmann, G; Yato-Kioka, M | 1 |
| Hiroe, M; Hosokawa, T; Ikeda, I; Ishiyama, S; Kasajima, T; Marumo, F; Nishikawa, T; Shimojo, T; Toyozaki, T | 1 |
6 review(s) available for pyrazines and Autoimmune Disease
| Article | Year |
|---|---|
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Drug Design; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2014 |
Treatment approaches to IgG4-related systemic disease.
Topics: Antibodies, Monoclonal, Murine-Derived; Autoimmune Diseases; Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunoglobulin G; Immunosuppressive Agents; Pancreatitis; Prognosis; Pyrazines; Recurrence; Rituximab | 2011 |
Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Topics: Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Drug Discovery; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; T-Lymphocytes | 2012 |
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Topics: Animals; Autoimmune Diseases; Boronic Acids; Bortezomib; Humans; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2012 |
Use of systemic proteasome inhibition as an immune-modulating agent in disease.
Topics: Animals; Autoimmune Diseases; Boronic Acids; Bortezomib; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; NF-kappa B; Proteasome Inhibitors; Pyrazines | 2007 |
6 other study(ies) available for pyrazines and Autoimmune Disease
| Article | Year |
|---|---|
Effects of dipeptidyl peptidase IV inhibitor sitagliptin on immunological parameters of lymphocytes in intact animals and animals with experimental autoimmune process.
Topics: Animals; Autoimmune Diseases; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Lymph Nodes; Lymphocytes; Male; Mice, Inbred CBA; Pyrazines; Sitagliptin Phosphate; Spleen; Thymus Gland; Triazoles | 2014 |
Bortezomib, C1-inhibitor and plasma exchange do not prolong the survival of multi-transgenic GalT-KO pig kidney xenografts in baboons.
Topics: Animals; Animals, Genetically Modified; Autoimmune Diseases; Boronic Acids; Bortezomib; Complement C1 Inhibitor Protein; Cytomegalovirus; Galactosyltransferases; Gene Knockout Techniques; Graft Survival; Heterografts; Immunity, Innate; Immunosuppressive Agents; Kidney; Kidney Transplantation; Models, Animal; Papio anubis; Plasma Exchange; Pyrazines; Sus scrofa; Virus Replication | 2015 |
Bortezomib: friend or foe of hemolytic anemia?
Topics: Anemia, Hemolytic; Animals; Autoimmune Diseases; Boronic Acids; Bortezomib; Evidence-Based Medicine; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Risk Assessment; Risk Factors | 2011 |
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2011 |
Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury.
Topics: Acute-Phase Reaction; Animals; Antibodies, Monoclonal; Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Concanavalin A; fas Receptor; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Quinolines; Rats; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Inhibitory effects of vesnarinone in the progression of myocardial damage in experimental autoimmune myocarditis in rats.
Topics: Analysis of Variance; Animals; Autoimmune Diseases; Biomarkers; Blotting, Northern; Female; Interleukin-1; Myocarditis; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pyrazines; Quinolines; Rats; Rats, Inbred Lew; Tumor Necrosis Factor-alpha | 1999 |